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Introduction: Deep brain stimulation (DBS) is widely used to improve quality of life in
movement disorders (MD) and psychiatric diseases. Even though the ability to have
children has a big impact on patients’ life, only a few studies describe the role of DBS
in pregnancy.
Objective: To describe risks and management of women treated by DBS for disabling
MD or psychiatric diseases during pregnancy and delivery.
Methods: We report a retrospective case series of women, followed in two DBS centers,
who became pregnant and went on to give birth to a child while suffering from disabling
MD or psychiatric diseases [Parkinson’s disease, dystonia, Tourette’s syndrome (TS),
Obsessive Compulsive Disorder (OCD)] treated by DBS. Clinical status, complications
and management before, during, and after pregnancy are reported. Two illustrative cases
are described in greater detail.
Results: DBS improved motor and behavioral disorders in all patients and allowed
reduction in, or even total interruption of disease-specific medication during pregnancy.
With the exception of the spontaneous early abortion of one fetus in a twin pregnancy,
all pregnancies were uneventful in terms of obstetric and pediatric management. DBS
parameters were adjusted in five patients in order to limit clinical worsening during
pregnancy. Implanted material limited breast-feeding in one patient because of local pain
at submammal stimulator site and led to local discomfort related to stretching of the
cable with increasing belly size in another patient whose stimulator was implanted in the
abdominal wall.
Conclusion: Not only is it safe for young women with MD, TS and OCD who have a
DBS-System implanted to become pregnant and give birth to a baby but DBS seems
to be the key to becoming pregnant, having children, and thus greatly improves quality
of life.
Keywords: deep brain stimulation, dystonia, obsessive compulsive disorder, Parkinson disease, pregnancy,
teratogenicity, Tourette’s syndrome
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Introduction
Deep brain stimulation (DBS) is considered as an effective treat-
ment in patients with advanced Parkinson’s Disease (PD) (1),
and medically poorly responsive movement disorders (MD) and
psychiatric diseases such as dystonia, Tourette’s syndrome (TS)
and obsessive compulsive disorder (OCD) (2–4). Recent studies
have shown that its early application improves quality of life, and
prevents psychosocial and functional impairment (5–7).
The ability to have children and a good family life has a
large impact on quality of life, especially in young patients (8,
9). Because caring for a child requires good health, having a
disabling progressive disease often prevents young women from
becoming pregnant. A number of authors (10–13) have, more-
over, reported worsening of MD and OCD during pregnancy,
exacerbated by a reduction in medical treatment to avoid possible
teratogenicity (14).
Deep brain stimulation improves patients’ clinical status and
allows reduction of medical treatment (1–3). Its non-systemic
action could, moreover, improve symptoms during pregnancy
without affecting fetal development.
We report a case series of patients affected by disabling neuro-
logical and psychiatric diseases who became pregnant while being
treated by DBS, and focus on patients’ psychomotor status and
treatment management during pregnancy and delivery.
Methods
We retrospectively included all patients affected by disabling
MD and psychiatric diseases operated on in our centers who
became pregnant while being treated by DBS.We collected demo-
graphic characteristics and histories of disease and pregnancy
from patients’ records. We assessed the clinical status before
(OFF and ON medication, after a supraliminal levodopa dose
for PD) and 1 year after surgery (OFF and ON DBS, OFF and
ON medication, after a supraliminar levodopa dose for PD) and
before, during, and after pregnancy (ON DBS, chronic medical
treatment), using the Unified Parkinson’s Disease Rating Scale
(UPDRS) motor score (part III) in PD; the Burke–Fahn–Marsden
Dystonia Rating Scale (BFMDRS) [motor score (MS) and disabil-
ity score (DS)] in dystonia and TorontoWestern Spasmodic Torti-
collis Rating Scale (TWSTRS) in cervical dystonia (patient 8); the
Yale Global Tic Severity Scale (YGTSS) in TS and the Yale-Brown
Obsessive Compulsive Scale (YBOCS) in OCD.We then collected
the non-available information through phone interviews.
The participants who were included in the study had given their
written informed consent according to the Center’s Review board
guidelines and the Declaration of Helsinki. All participants gave
their informed consent to report their personal and medical data
in this clinical cases study. Our Centers did not require ethical
Abbreviations:BFMDRS, Burke–Fahn–MarsdenDystonia Rating Scale; C-section,
cesarean section; DBS, deep brain stimulation; MD, movement disorder; OCD,
obsessive-compulsive disorder; PD, Parkinson disease; TS, Tourette’s syndrome;
TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; UPDRS, Unified
Parkinson’s Disease Rating Scale; YBOCS, Yale-BrownObsessive Compulsive Scale;
YGTSS, Yale Global Tic Severity Scale.
board approval for the treatments presented in the manuscript and
to publish retrospective and anonymous data, with no statistical
result.
Patient Characteristics Before and
After DBS
Eleven patients (three PD, five dystonic, two TS and one OCD
patients) were included between 2010 and 2014. Six patients were
operated on at the Grenoble University Hospital and five at the
Munich Ludwig-Maximilians University.
Before DBS, all PD patients had developed severe motor fluctu-
ations and dopamine dysregulation syndromes with severe behav-
ioral disorders resulting in fateful outcomes such asmarital break-
down, loss of child custody, depression, and suicidal ideation. All
dystonic, TS, and OCD patients had drug resistant symptoms or
drug side effects and very low levels of social functioning, avoiding
contact. Themean ageSD at DBS (bilateral subthalamic nucleus
for PD, OCD and one dystonic patient; bilateral globus pallidus
internus for dystonia and TS) was 27.5 7.0 years. Pulse genera-
tors (Medtronic: Kinetra Dual channel in seven patients, Soletra
in one patient, Activa PC dual-channel in three patients) were
implanted in subclavicular (eight patients) or abdominal (three
patients) sites.
Deep brain stimulation induced a clear symptomatic improve-
ment in all patients, and this was confirmed by scores on 12-
month post-DBS clinical assessment scales (see Table 1). PD
patients experienced a reduction in their motor symptoms, fluc-
tuations, and behavioral disorders. In one PD patient (patient 2),
minimal left side rigidity, akinesia and apathy persisted 1 year
after DBS. Functional ability improved in all dystonic patients.
Because of progressive worsening of dystonia almost 1 year after
surgery, a second globus pallidus internus DBS was performed
on patient 7 6 years later. TS patients experienced tic reduc-
tion, and behavioral improvement was noted in TS and OCD
patients.
Deep brain stimulation permitted a reduction in medical treat-
ment (see Table 1). After DBS, the levodopa equivalent daily dose
was reduced from 555 to 205mg/day in patient 1 and from 760 to
325mg/day in patient 3 and was increased from 420 to 500mg/day
in patient 2 (15).
One dystonic patient (patient 7), the OCD and the TS patients
stopped their treatment, while another dystonic patient (patient
4) reduced it by 90%. The others had no treatment before or after
surgery.
Patients’ Pregnancies
Prior to DBS, two PD patients had had one and two elective
abortions, respectively, either because of a fear of treatment’s
effects on the fetus or of their behavioral dopamine dysregulation
syndromes. One patient had had two spontaneous abortions for
unknown reasons (the first when taking levodopa, the second
when taking rasagiline, trihexyphenidyl, and levodopa). Two PD
patients and the OCD patient had had two and three healthy
pregnancies, respectively.
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TABLE 1 | BS effects on clinical assessment scales and treatment management.
Patients Disease Scale scores Medical treatment
Before DBS After DBS Before DBS After DBS
Off Med On Med Off Med
Off Stim
Off Med
On Stim
On Med
Off Stim
On Med
On Stim
1 Parkin
mutation PD
42/108 19/108 43/108 28/108 15/108 9/108 L-dopa-carbidopa- Pramipexole CR
1.05mgentacapone 350mg
Pramipexole 0.9mg Rasagiline 1mg
2 Parkin
mutation PD
29/108 5/108 39/108 24/108 27/108 11/108 L-dopa-benserazide
300mg
Piribedil 300mg
Ropinirole 6mg
3 Parkin
mutation PD
30/108 4/108 35/108 19/108 8/108 4/108 L-dopa-benserazide
600mg
Bromocriptine 15mg
Ropinirole CR 8mg L-carbidopa CR 200mg
4 Post-anoxic
dystonia
NA MS 24/120 NA NA NA MS 5/120 Clonazepam 3mg Clonazepam 0.3mg
DS 6/29 DS 2/29
5 DYT 1
Dystonia
MS 32/120 NA NA MS 6/120 NA NA No No
DS 14/29 DS 4/29
6 DYT 1
Dystonia
MS 40/120 NA NA MS 10/120 NA NA No No
DS 16/29 DS 4/29
7a DYT 1
Dystonia
NA MS 26/120 NA MS 1/120 NA NA Trihexyphenidyl
15mg
No
DS 9/29 DS 0/29
Baclofen 100mg
8 Primary
segmental
dystonia
22/87 NA NA 2/87 NA NA No No
9 TS NA 89/100 NA 32/100 NA NA Sertraline 100mg No
Haloperidol 5mg
Valproic acid 600mg
10 TS NA 91/100 NA 30/100 NA NA Sertraline 150mg No
Olanzapin 5mg
11 OCD NA 22/40 NA 12/40 NA NA Escitalopram 30mg No
Clinical assessment scale scores and medical treatment before (Off and On medication, after a supraliminar levodopa dose for PD) and 1 year after DBS (Off and On DBS, Off and On
Medication, after a supraliminar levodopa dose for PD) are listed. We reported the Unified Parkinson’s Disease Rating Scale (UPDRS) motor score (part III) in PD; the Burke–Fahn–Marsden
Dystonia Rating Scale (BFMDRS) [motor score (MS) and disability score (DS)] in dystonia and Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in cervical dystonia (patient
8); the Yale Global Tic Severity Scale (YGTSS) in TS and the Yale-Brown Obsessive Compulsive Scale (YBOCS) in OCD.
NA, not available; Med, medication; Stim, stimulation.
aFirst DBS.
After DBS, ten patients had one pregnancy, and one patient
(patient 9) had two. The mean delay between DBS and pregnancy
was 4.7 3.4 years (mean SD).
During pregnancy underDBS, four patients reported no change
in their clinical status, two reported clinical improvement and
five mild clinical worsening (patient 9 in both pregnancies) with
an increase in severity of fatigue, motor fluctuations, dystonia
or tics.
Apart from two PD patients (one patient from the 6month of
pregnancy only), patients took no medication during pregnancy
(see Table 2). DBS was adjusted to improve symptoms in five
patients (see Table 2).
All deliveries occurred at full term. Three patients had vaginal
births while the others had cesarean sections (C-section) (one due
to the baby’s abnormal position, one to avoid clinical impairment
at delivery, one due to previous C-section, and the others because
of the unknown risks of delivery on implanted devices). The
C-section was performed according to the own protocol of each
obstetrical center.
All babies were healthy and had a normal course of devel-
opment. One patient experienced spontaneous abortion of one
fetus in the first weeks of a twin pregnancy. Her second baby was
healthy on delivery.
Eight patients breastfed their babies. PD patients on oral
treatment, however, did not, because of the unknown toxicity
of medication. One dystonic patient was unable to breastfeed
because of pain at the submammary stimulator site.
After delivery, the conditions of two patients worsened tem-
porarily. Another patient experienced chronic progressive wors-
ening of her dystonia. This improved after electrode implantation
in the subthalamic nucleus. Conversely, TS patients reported an
improvement. While medical treatment was reintroduced in PD
patients, dystonic patients who had discontinued treatment before
pregnancy remainedOFF treatment. Stimulation parameters were
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TABLE 2 |Medical treatment and DBS parameters during pregnancy.
Patients’ pregnancies Medical treatment DBS parameter changes
during pregnancy
Before pregnancy During pregnancy After pregnancy
1 Pramipexole CR 1.05mg No Pramipexole CR 1.05mg
rasagiline 1mg
No
Rasagiline 1mg
2 Ropinirole 14mg Levodopa 200mg Ropinirole 10mg No
3a Rasagiline 1mg ropinirole 2mg
trihexyphenidyl 150mg
Rasagiline 1mg ropinirole 2mg
trihexyphenidyl 150mg
Rasagiline 1mg ropinirole 2mg
trihexyphenidyl 150mg
No
4 Clonazepam 0.3mg No No Yes, voltage decrease
5 No No No No
6 No No No No
7 Baclofen 100mg No No Yes, voltage increase
8 No No No No
9 (1) No No No Yes, voltage increase
9 (2) No No No Yes, voltage increase
10 No No No Yes, voltage increase
11 No No No Yes, voltage increase
The table shows medical treatment and DBS parameter management in each patient’s pregnancy.
aOn medication from the 6month of pregnancy. Patient 9 (1, 2): first and second pregnancy.
set at pre-pregnancy levels in TS patients 3months after delivery.
They were changed for two patients whose condition worsened
after delivery.
The pulse generator battery required replacement a few days
after delivery in two patients and during pregnancy in one. One
patient complained of discomfort accompanied by a sensation of
“tension” along the extension cable (abdominal stimulator site)
during pregnancy.
At the final follow-up (19.0 14.8months after delivery;
mean SD) all patients were independent and able to take care
of their babies.
Illustrative Clinical Cases
First Clinical Case: A PD Patient
This case illustrates the role of DBS on motor symptoms and
social adjustment in PD with motor and non-motor levodopa
complications. Patient 1 developed PD due to Parkin mutation
at the age of 19. A few years after the onset of PD, she married
and had two pregnancies (two daughters, one healthy and the
other suffering from a severe atrial defect). Like most young PD
patients, she progressively developed motor complications such
as painful OFF dystonia and dyskinesia. By the time she was 34,
these had become disabling. The dopamine agonist daily dosage
was increased to improve motor fluctuations and, when taking
pramipexole 2.1mg/day, she developed severe dopamine dysreg-
ulation syndrome with hypersexuality, compulsive shopping and
nocturnal hyperactivity. She became pregnant for a third time but
aborted quickly because of the fear of possible teratogenic effects
of her treatment. The family equilibrium was upset, she divorced
and lost custody of the children. Since her quality of life was
progressively worsening because of her motor fluctuations and
behavioral disorders, she underwent subthalamic nucleus DBS
(Medtronic DBS 3389 electrodes, pulse generator Kinetra) in 2009
at the age of 35. DBS greatly improved her motor symptoms
(UPDRS III fell from 19/108 to 9/108 ( 52.6%) and fluctuations
and allowed for a reduction in dopaminergic treatment, with a
subsequent improvement in her behavior. One year after surgery,
she was allowed to bring her daughters back home and to care for
them on her own. Two years after surgery, she met a new partner
and decided to have another child. During pregnancy, she was
able to stop dopaminergic treatment without any complication
or worsening of symptoms. Delivery occurred at full term by C-
section because of the baby’s abnormal position. She was able to
breastfeed her baby safely. Some weeks after delivery she noticed
an occasional worsening of right leg dystonia and impairment in
walking, but her UPDRS motor score remained unchanged. She
now lives alone during the week with her three daughters, as her
partner lives and works away from home.
Second Clinical Case: A TS Patient
This case illustrates the effect of DBS on psychosocial competence
in patients with neuropsychiatric diseases. Patient 9 developed
TS at the age of 6. Her symptoms included severe coprolalia,
consistingmainly of politically incorrect words, and self-injurious
behavior such as burning her skin with an electric iron, cutting
her hair, and painting on her skin. Her level of social functioning
was extremely low – she lived only with her partner and walked
her dog at night to avoid meeting other people. Acute 12-fold
electroconvulsive therapy had suppressed tics andwas followed by
8-monthly maintenance treatment, which had to be discontinued
due to non-convulsive status epilepticus. As a result, posteroven-
trolateral globus pallidus internus DBS (Medtronic DBS 3387
electrodes, pulse generator Kinetra) was performed at the age of
28. DBS reduced almost all symptoms within 12months [(Clin-
ical Global Impression scale: from 6 to 3/7, TS Global Scale:
from 71.3/100 to 14/100 ( 80%), YGTSS: from 89/100 to 32/100
( 64%)] allowing her to return to part time work in her previous
occupation as an administrative assistant. Postoperatively, and
having discontinued any TS-specific medication, she married,
became pregnant and gave birth to a healthy boy. In the 34th
week of pregnancy, the pulse generator battery had almost run out
and required replacement; the patient’s obstetrician/gynecologist
had to put this on stand-by in case the patient required an
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emergency C-section. No complications occurred during battery
replacement. With her tics almost completely suppressed and able
to do without medication, the patient became pregnant for a
second time and gave birth to another healthy boy (16).
Discussion
In our case series, MD patients had disabling motor symptoms.
All PD, TS, and OCD patients had developed severe behavioral
disorders resulting in fateful outcomes such asmarital breakdown,
loss of child custody, depression, and suicidal ideation or avoid-
ance of social contact, which all compromised the possibility of
having children.
Deep brain stimulation induced clinical and behavioral
improvement and permitted the reduction of medical treatment,
in linewith the literature (1–4). It therefore contributed to the pos-
sibility of having and rearing children, and limited fetal exposure
to medication.
With the exception of the spontaneous abortion of one fetus
within the first weeks of a twin pregnancy, all pregnancies were
uneventful. As previously reported, our study revealed conflicting
data on patients’ clinical status during pregnancy (10–13, 17,
18). Most women were, however, able to go to term with no
difficulty. Some case reports, concerning mainly PD, have shown
possible disease worsening during pregnancy or in the postpar-
tum period (10–12) while other reports claim to have noted no
change or even improvement (17, 18). Few uneventful pregnan-
cies have been described in women with dystonia treated by
DBS (19, 20).
In our study, DBS adjustments limited clinical worsening in five
patients and allowed nine out of eleven women to take their preg-
nancies to term without treatment. Uneventful pregnancies have
been described in MD and OCD patients on medical treatment
(9–14, 17, 18, 21–24).However,mostmedications used inMDand
OCD are considered pregnancy class C due to the lack of evidence
about their impact on fetal development and teratogenic risk (9,
23, 24). Women are, therefore, often forced to reduce or change
their treatment, with ensuing clinical worsening (14, 25). Our data
support the idea that, because of its non-systemic action, DBS
could be a better way than medical treatment alone of controlling
patients’ symptoms during pregnancy.
A growing number of women of childbearing-age have a DBS-
system. To our knowledge, our case series is the largest avail-
able and we did not encounter any major adverse effects related
to DBS. Two patients had routine battery replacements, a few
days after delivery and one required battery replacement under
local anesthetic during pregnancy. These cases underline the
need to anticipate battery replacement in planned pregnancies
in order to avoid surgery and possible worsening of symptoms
during pregnancy.One patient was unable to breastfeed because of
pain at the neurostimulator site (submammary site) and another
one experienced discomfort accompanied by a sensation of ten-
sion in the abdominal skin along the extension cable (abdom-
inal site) toward the end of pregnancy when increasing belly
size stretched the cable. These side effects support the need
to consider different device-related options in childbearing-age
patients who wish to become pregnant. C-sections were per-
formed on five patients because of the lack of evidence regard-
ing natural birth under DBS. We did not report any com-
plication during natural birth in our patients. This supports
the safety of DBS during pregnancy and at delivery for both
mother and child if the underlying disease is well controlled
by DBS.
Our report had several limits. First, because of its retrospective
nature, data collection was not complete and scale scores were not
available for all patients. This limited the possibility of objectively
confirming clinical changes in all clinical assessments. We were,
in addition, unable to quantify daily life activities and quality of
life changes. Second, even though it is the largest series available,
our sample remains small and prospective and larger studies are
needed.
In conclusion, because of the effectiveness of DBS on psy-
chomotor status and treatment reduction, our report suggests it
has a potential role in the management of young women suffering
from disabling MD and OCD who wish to become pregnant. It
also stressed the need to define strategies to prevent and control
any worsening of patients’ condition during pregnancy, and to
consider device-related options, such as choice of stimulator type
(mono or dual-channel, primary cell or rechargable) and implan-
tation site (subclavicular and abdominal) in women who plan to
become pregnant.
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